Thermo Fisher Scientific and Illumina  have signed a commercial agreement that enables Illumina to sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing (NGS) platforms. The best-in-class amplicon technology is highly effective in capturing DNA and RNA from minute amounts of samples for application in multiple areas of research.

Under the agreement, Thermo Fisher will provide Illumina with Ion AmpliSeq technology for research use. Illumina will sell the product directly to its customers under the name AmpliSeq for Illumina. Thermo Fisher will continue to sell Ion AmpliSeq chemistry for both IVD and RUO applications to Ion Torrent NGS customers, and retains the right to make the technology available on other next-generation sequencing platforms.

“Thermo Fisher expects standardization on the AmpliSeq technology will have a profound impact on disease research and encourage greater collaboration among the NGS community,” said Joydeep Goswami, president of Clinical Next-Generation Sequencing and Oncology for Thermo Fisher Scientific. “Through this agreement, a much larger base of research customers can now leverage Ion AmpliSeq technology’s benefits, while Thermo Fisher continues its commitment to Ion Torrent targeted sequencing solutions for the research market and accelerates its focus and forward momentum in the clinical space.”

The agreement enables Illumina customers to utilize targeted resequencing as a follow-up to larger-scale exome and whole genome discovery studies. Ultimately, the agreement supports both organizations’ commitment to drive scientific advancement in human disease research by providing complete NGS workflow solutions.

“This partnership represents a significant step forward enabling a high performing, flexible amplicon chemistry for use on Illumina’s market-leading portfolio of sequencing systems,” said Mark Van Oene, chief commercial officer for Illumina. “By expanding access to AmpliSeq chemistry to existing customers, we are enabling them to do even more with their systems.”

Introduced to the market in 2011, Ion AmpliSeq technology was developed to facilitate amplicon sequencing on the Ion Torrent NGS systems. The technology leverages highly multiplexed polymerase chain reaction (PCR) to quickly and easily capture DNA or RNA targets from very limited samples. It has since proven to be a highly desired and effective NGS amplicon sequencing solution for its ease-of-use, scalability, efficient workflow and ability to provide trusted data in multiple NGS research application areas. To date, more than 1,100 Ion AmpliSeq technology studies have been published in peer-reviewed scientific journals.    - Medical Buyer Bureau 


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version